Remarkable progress has occurred in the treatment of patients with acute promyelocytic leukemia (APL) since the introduction of all-trans retinoic acid (ATRA). Acute promyelocytic leukemia accounts for 10-15% of de novo cases of acute myeloid leukemia (AML) in younger adults and is characterized by a reciprocal translocation that involves chromosomes 15 and 17.
1,2 The chromosome 15 breakpoint falls within the area of the PML gene, while the chromosome 17 breakpoint is located in the locus that encodes the retinoic acid receptor (RAR-␣). 3, 4 The resulting fusion gene, PML-RAR-␣, encodes a chimeric protein that causes a maturation arrest at the promyelocytic stage of myeloid cell development. Expression of the t(15;17) translocation is strictly limited to neoplastic promyelocytes. Excluding anecdotal case reports of the t(15;17) translocation in promyelocytic blast crisis in chronic myelogenous leukemia, this cytogenetic abnormality has never been reported in any other neoplastic disease. 5 This observation suggests that this translocation is important in the pathogenesis of APL. Such insights into the molecular genetics coincided with laboratory observations that retinoic acid promoted maturation of leukemic promyelocytes in vitro. 6 Together, these findings paved the way to incorporate ATRA in the treatment of APL. Contemporary strategies for newly diagnosed patients with APL include ATRA and anthracycline-based chemotherapy for induction, anthracycline-based consolidation, and in some patients, a prolonged course of maintenance therapy. With this approach, 70-80% of patients appear to be cured. [7] [8] [9] However, the best treatment of patients with relapsed disease is less defined. Both autologous (AUTO) and allogeneic (ALLO) hematopoietic stem cell transplantation (HSCT) are established treatments for patients with AML. [10] [11] [12] Allogeneic transplantation may be the only curative therapy for some patients with advanced AML. 12 However, controversies exist as to which patients will benefit from either transplant. Since APL appears to be highly curative with ATRA plus chemotherapy, it is timely and important to address the role of transplantation in APL.
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Current approach to newly diagnosed patients with APL
All-trans retinoic acid selectively differentiates leukemic promyelocytes into mature granulocytes both in vitro, and in vivo. [13] [14] [15] [16] [17] Initial phase II trials with ATRA showed that remission is induced in most patients with rapid resolution of the coagulopathy. [18] [19] [20] Fenaux and colleagues 21 demonstrated the benefit of adding chemotherapy (daunorubicin and cytarabine) to ATRA for induction compared with chemotherapy alone in newly diagnosed patients. The event-free survival (EFS) was estimated to be 80% in the ATRA group compared with 50-55% in the chemotherapy arm ( Figure 1) . In a pivotal multicenter intergroup trial, patients with newly diagnosed APL were randomly assigned to either ATRA alone or chemotherapy (daunorubicin and cytarabine) as the induction regimen, and ATRA maintenance or observation following intensive consolidation. 7 In this study, ATRA given during induction or maintenance therapy improved disease-free survival (DFS) and overall survival (OS) compared to chemotherapy alone. The European APL Group randomized patients to ATRA followed by chemotherapy, or concurrent ATRA plus chemotherapy. 9 The concurrent regimen resulted in a lower relapse rate (RR), and improved EFS than the sequential therapy arm. The maintenance regimens were either intermittent ATRA for 15 days every 3 months, continuous chemotherapy with 6-mercaptopurine and methotrexate, or the combination. This trial showed clear benefit with maintenance therapy in terms of RR that was 11% in the chemotherapy maintenance group compared to 27% in patients who received no chemotherapy maintenance. The 2-year RR was 13% in the patients who were assigned to ATRA maintenance as compared with 25% in those patients who did not receive ATRA. A major contribution to the field was made by investigators in the Spanish cooperative group PETHEMA who used anthracycline-based therapy without cytarabine in induction or consolidation. These investigators showed that the DFS, OS, and EFS were 92%, 82%, and 79%, respectively, at 2 years. 8 This suggested that omitting cytarabine from the treatment regimen does not affect outcome, and potentially can minimize side-effects. An earlier report by Estey and colleagues 22 suggested similar results. Some investigators studied the advantage of reducing the ATRA dose for induction therapy. 23, 24 Although results were promising and comparable with historical controls, it is premature to reach a conclusion without longer followup.
It is now clear that all newly diagnosed patients with APL should be treated with ATRA at 45 mg/m 2 /day at a divided dose until CR. It has become routine to administer concurrent single agent anthracycline chemotherapy, and the addition of cytarabine does not appear necessary. 8 Consolidation therapy is usually anthracycline-based with either daunorubicin, or idarubicin for two cycles. Maintenance therapy is generally an accepted approach, particularly in older adults or those presenting with a white blood cell count over 10 000/l, but the optimal dosage of ATRA or low-dose chemotherapy is unresolved. A recent trial used maintenance therapy with 90 mg/m 2 /day of 6-MP orally, 15 mg/m 2 /week of MTX, and 45 mg/m 2 /day of ATRA for 15 days every 3 months. 9 With this regimen the 2-year OS and EFS were 82% and 79%, respectively.
Identifying patients at high risk for relapse is important in APL. This subset of patients might potentially benefit from high-dose therapy and transplantation. Recently, this issue was addressed by Sanz and colleagues. 25 These investigators reported a collaborative study from the GIMEMA and PETHEMA trials in newly diagnosed patients. All patients received identical induction and maintenance therapy. This analysis concluded that initial leukocyte count (WBC) and platelets count were the only variables with independent prognostic value. Patients with WBC Ͻ10 ϫ 10 9 /l and platelet count Ͼ40 ϫ 10 9 /l were classified as low risk for relapse, those with WBC Ͼ10 ϫ 10 9 /l high risk and those with WBC Ͻ10 ϫ 10 9 /l and platelet count Ͻ40 ϫ 10 9 /l intermediate risk.
Current approach to relapsed APL patients
With advances in the management of APL, the relapse rate in patients treated initially with ATRA has decreased to approximately 20% compared with almost 60-70% historically. 26 Recently, investigators from China showed that with relapsed APL patients had an excellent response to arsenic trioxide. [27] [28] [29] Initial studies suggested that arsenic induces apoptosis, but other studies showed that arsenic also induces differentiation after prolonged exposure. [30] [31] [32] Soignet and colleagues 33 published a pilot study of 12 patients with relapsed APL treated with arsenic trioxide in doses ranging from 0.06 to 0.2 mg/kg/day until visible leukemic cells were eliminated from the bone marrow. Eleven of the 12 patients achieved CR. The median duration of therapy in the 11 patients who responded to treatment was 33 days, the median daily dose was 0.16 mg/kg, and the CR was attained by a median of 47 days after the initiation of therapy. Three of those 11 patients relapsed during their second course of therapy, and none of these relapsed patients had achieved molecular negativity by RT-PCR. Recently reported follow-up results showed an overall response rate of 87% after treatment with arsenic trioxide. 34 The molecular conversion was noted in 78% of patients, and 69% of patients who achieved CR remain alive and well at a median follow-up of 18 months.
Evidence also exists that re-treatment with ATRA alone or with chemotherapy can induce CR in relapsed patients although these studies suggested that a 6-7 month ATRAfree period is required before re-instituting ATRA. 35, 36 Importantly, ATRA induced CR in relapsed patients who were previously treated with ATRA or with chemotherapy. 37 The best choice of therapy in relapsed patients is still under investigation. It is acceptable to treat relapsed patients with ATRA if they were not treated with this agent previously, or if the ATRA-free period is 6-12 months. However, arsenic trioxide is emerging as the treatment of choice for relapsed patients. The role of stem cell transplant in this setting is less well defined.
The issue of molecular relapse
Although ATRA induces CR by morphologic criteria, the neoplastic clone is not eliminated when it is used as a single agent, and patients remain molecularly positive by RT-PCR. Persistence of the neoplastic clone indicates a high likelihood of clinical relapse. 38 Currently, RT-PCR for PML-RAR-␣ is the most widely used method for genetic diagnosis of APL. 39, 40 RT-PCR permits detection of minimal residual disease (MRD) and direction of patient management.
Overall, there is general agreement that a positive PML-RAR␣ test after consolidation strongly predicts subsequent hematologic relapse whereas repeatedly negative results are associated with long-term survival in the majority of patients. [41] [42] [43] However, this correlation is not absolute as some patients who are PCR positive remain in long-term remission, and others ultimately relapse after a negative test. [44] [45] [46] Although assessment of the PCR status immediately following the end of consolidation has little prognostic value, subsequent monitoring during the early post-treatment period appears informative and affects management of this disease. Recently, Diverio and colleagues 42 reported the results of a prospective study in which 163 patients who were induced into remission with ATRA combined with chemotherapy were tested at regular pre-established time intervals after the end of treatment. Twenty of 21 patients who converted to a positive PCR relapsed within a median time of 3 months, whereas the 3-year estimate of relapse risk for patients who tested negative more than twice post consolidation was less than 10%. Patients who converted to a positive PCR were salvaged with early treatment prior to the development of overt disease. 47 It is currently accepted that the persistence of a negative PCR confirmed in at least two successive marrow samples at the end of treatment might be regarded as the best available therapeutic goal. 48 It is anticipated that therapy at the time of molecular relapse would minimize the mortality rate observed with re-induction of overt disease, but studies are underway to assess the best approach for patients who have a confirmed molecular relapse with clinical, morphologic, and hematologic remission.
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Stem cell transplantation for patients with APL
Some nonrandomized and randomized studies showed improved long-term DFS after transplantation for AML patients in CR1 compared with conventional chemotherapy, although others did not confirm these findings. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] Since APL has become a highly curable disease, questions have been raised about the benefits of stem cell transplantation as a consolidation maneuver for patients in CR1. Mandelli and colleagues 59 reported the outcome of APL patients transplanted and reported to the European Blood and Marrow Transplantation group (EBMT). In this survey, investigators reported 362 patients, 187 of whom had an AUTO-HSCT, and 175 had ALLO-HSCT. The majority of these patients were transplanted in CR1. The results of this retrospective study suggested that about 45% of patients undergoing a transplant could be cured regardless of the modality used. The leukemia-free survival (LFS) in patients transplanted in CR1 was 48% for AUTO-HSCT, and 42% for ALLO-HSCT. However, TRM was 19% and 42%, respectively. Patients who were transplanted in CR2 had a LFS of 32% for AUTO-HSCT and 22% for ALLO-HSCT with a TRM of 23% and 41%, respectively.
Several important limitations of this retrospective analysis are apparent. First, it is not clear if any patients were exposed to ATRA. Second, the study was retrospective. Third, this cohort included both children and adults, which makes the information difficult to interpret. Fourth, this analysis lacked molecular correlation.
Despite the limitations of this study, the information provides some perspective. Since combined ATRA and chemotherapy currently would produce 70-80% potential cure in newly diagnosed patients, it is difficult to recommend ALLO-HSCT as a consolidation strategy. Most studies report a TRM rate in the range of 20%. There are no comparative trials between patients who were maintained on long-term therapy with ATRA compared to those who were transplanted. Therefore, at this time there is little role for stem cell transplantation in patients who achieve CR1 with molecular remission after contemporary treatment. It is crucial however, to continue following their molecular status, and intervene when this changes.
Stem cell transplantation for APL patients after CR2
Most reports of APL patients transplanted in CR2 were published prior to the introduction of arsenic trioxide (Tables 1 and 2 ). Since relapsed APL patients have a high probability of achieving CR2, the choice of post-remission therapy after CR2 is a critical issue. 54 Meloni and colleagues 60 reported 15 consecutive patients with relapsed APL who underwent AUTO with unpurged marrow. Thirteen patients received anthracycline-based chemotherapy as first-line treatment, whereas two were treated by combined ATRA and idarubicin. All patients received three cycles of consolidation therapy. The CR1 duration ranged from 6 to 40 months. Second CR was achieved in all patients with oral ATRA. All but three patients received consolidation therapy with intravenous cytarabine at 1 g/m 2 days 1 to 4 and i.v. mitoxantrone at 6 mg/m 2 1 and 2days 1 to 4. The median time interval from the achievement of CR2 to AUTO-HSCT was approximately 2 months. In this study, six out of 15 patients (45%) remained alive and well, and they also remain in molecular remission. All seven patients who underwent AUTO-HSCT with persistent PCR-detectable MRD in their BM cells relapsed within 9 months after transplant, which confirms the value of PCR positivity during remission as a predictor of relapse in APL. Only one patient with negative PCR relapsed, and one developed secondary leukemia. The patient with secondary leukemia, however, received a different preparative regimen. It can be concluded from this study that patients with negative PCR after their CR2 will fare favorably with AUTO-HSCT, and patients with posi- Table 2 Results of allogeneic hematopoietic stem cell transplantation in APL The 2nd relapse patient died at 3 months. CR = complete remission; ATRA = all-trans retinoic acid; N/A = not available; LFS = leukemia-free survival; OS = overall survival; TRM = transplantrelated mortality; GVHD = graft-versus-host disease.
tive PCR should not be offered transplant as a routine procedure. It is impossible to speculate, based on this study alone, what the outcome would be after ALLO-HSCT, and whether the PCR results would have the same impact. In addition, these patients were treated prior to the routine use of ATRA as a primary therapy, or as a therapy for relapsed disease. Roman and colleagues 43 reported 20 patients in longterm remission after bone marrow transplantation. Ten patients had undergone AUTO-HSCT and 10 had an ALLO-HSCT. Of the eight patients studied just before conditioning, five showed detectable transcripts prior to transplantation. Three of them were in CR and became PCR negative early post transplant. The other two patients not in CR before transplant, remained PCR positive, relapsed, and died early after transplant. These data suggest that long-term remission after HSCT in APL patients is associated with eradication of cells carrying the PML-RAR␣ transcript, and that continued positivity predicts subsequent relapse.
However, it is important to note that a policy of excluding all patients with a positive PML/RAR␣ from transplant may not be necessary. Sanz and colleagues 61 reported a patient with APL in CR2 and in molecular remission in the bone marrow just prior to conditioning, and who received a PBSC bearing cells with the PML/RAR␣ transcript. The patient was still well and alive after 22 months. This report and others suggested that autologous PBSC transplantation may be worth considering in patients with APL despite the presence of positive PCR in the stem cells collected. 62 A recently published trial by Thomas et al 37 evaluated 50 patients with APL in first relapse, of whom 39 had been previously treated with ATRA, who were randomized to oral ATRA until remission followed by timed sequential chemotherapy combining etoposide, mitoxantrone, and cytarabine (EMA) for two cycles. Ninety percent of patients were in CR after induction. Five patients died from infection during aplasia following EMA chemotherapy. Eleven patients who achieved CR had an HLA-identical donor and underwent allogeneic transplantation. The median DFS of allografted patients was 8.2 months. The other 34 patients in CR were scheduled for AUTO-HSCT, but only 22 of these were transplanted since some had either early relapse, failure to harvest adequately, withdrawal from study, or severe chemotherapy-related toxicity. The 3-year DFS for patients actually autografted was 77%. This study demonstrated the feasibility of transplant in relapsed APL after re-induction with ATRA combined with EMA chemotherapy, and that allogeneic transplant may be too toxic in this setting.
A more recent survey from the EBMT was reported recently by Sanz and colleagues 63 in abstract form. These investigators reported on 542 patients transplanted after the advent of ATRA. Of these, 143 patients underwent AUTO-HSCT while 121 had an ALLO-HSCT, both in first CR. In the second CR, 151 patients underwent AUTO-HSCT while 127 had an ALLO-HSCT. The results are summarized in Table 3 .
These results did not vary significantly when age subgroups were analyzed. This survey showed a remarkably low RR in the group undergoing allograft in CR2. Interestingly, this RR remained similar to that of patients receiving Table 3 Results of hematopoietic stem cell transplantation in APL after 1993 from the European Blood and Marrow Transplant Group at 6 years. (The exact proportion of patients who had received ATRA as part of their therapy prior to HSCT was not specified) Bone Marrow Transplantation the same procedure in CR1. Although these results suggest a lower RR in patients undergoing an ALLO-HSCT in CR2, the impact is minimized, once LFS and OS data are taken into consideration, due to high TRM. There are some similarities between this study, and the prior survey reported by Mandelli and colleagues. 59 Both studies clearly showed that TRM is higher with ALLO-HSCT in CR1 and CR2. Both studies also showed that LFS was higher in ALLO-HSCT in CR2. Combining the data from both studies, it can be concluded that ALLO-HSCT is not a viable option in CR1 due to high TRM, but can be considered in CR2 in patients with poor prognosis.
OS
Data from the IBMTR show similar results with better OS, LFS, and lower RR when undergoing a transplant procedure at CR1 compared with CR2 (Figures 2 and 3) . Prior exposure to ATRA had little effect on the LFS and OS in patients who underwent an ALLO-HSCT (Figures 4 and 5 ).
Conclusions and future directions
Acute promyelocytic leukemia represents the paradigm of targeted therapy. The treatment of this disease has changed dramatically over the past two decades and continues to evolve. Since the introduction of ATRA and arsenic trioxide in the management of this disease, APL has become the most curable subtype of AML in adults. It has become increasingly important to define the role of HSCT.
Currently, there is little role for ALLO-HSCT in CR1, as the toxicity of the procedure is substantial and the outcome with current ATRA-based strategies is excellent. Any potential benefit in high risk patients remains to be determined. In relapsed patients it is feasible to obtain a second CR either with arsenic trioxide or with re-treatment with ATRA with or without chemotherapy. In CR2 it is acceptable to recommend a transplant procedure. The initial outcome of patients induced into remission with arsenic trioxide is excellent. However, many patients relapse and there may be a benefit for post-arsenic chemotherapy. The outcome of ASCT with molecularly negative cells is excellent and the TRM associated with ALLO-HSCT may be avoided. The ability to detect MRD by molecular studies provides the unique opportunity to collect uncontaminated stem cells.
Since the TRM with AUTO-HSCT is now very low, the addition of AUTO-HSCT in CR1 for high risk patients could be tested. Such treatment should be performed in the context of a well-designed clinical trial with careful monitoring of molecular studies.
